A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Jazz Pharmaceuticals plc
JAZZ
$15.5B
Mkt Cap
$253.87
-0.39%
Jazz Pharmaceuticals plc (JAZZ) has a 5-year average return on invested capital (ROIC) of 3.7%. This is below average and may indicate limited pricing power.
Jazz Pharmaceuticals plc (JAZZ) has a market capitalization of $16.8B. It is classified as a large-cap stock.
Jazz Pharmaceuticals plc (JAZZ) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.75%.
Jazz Pharmaceuticals plc (JAZZ) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Jazz Pharmaceuticals plc (JAZZ) reported annual revenue of $4.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Jazz Pharmaceuticals plc (JAZZ) has a net profit margin of -8.3%. The company is currently unprofitable.
Jazz Pharmaceuticals plc (JAZZ) generated $1.3 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing life-changing medicines for patients with rare diseases, often with limited or no therapeutic options. The company operates across three primary segments: sleep disorders (led by Xywav, a low-sodium oxybate treatment for narcolepsy and idiopathic hypersomnia, and the legacy Xyrem product), epilepsy (anchored by Epidiolex, a cannabidiol oral solution for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex), and rare oncology (including Ziihera for HER2-positive biliary tract cancer and gastroesophageal adenocarcinoma, Modeyso for diffuse midline glioma, Zepzelca for small cell lung cancer, and Rylaze for acute lymphoblastic leukemia). Jazz's business model emphasizes efficient, concentrated commercialization targeting small patient populations with high unmet medical needs, leveraging an integrated global infrastructure and scalable operating model to reach patients worldwide. The company pursues a strategy of strong commercial execution, pipeline advancement through both internal R&D and strategic acquisitions, and disciplined capital allocation to build a durable portfolio of differentiated therapies. Distribution is supported by exclusive partnerships (such as with Onco360 for oncology) and comprehensive patient support services, while the company's competitive moat derives from its scientific expertise in rare disease, first-mover advantages in specific indications, and the durability of its approved therapies across geographies including the United States, Europe, Canada, and other international markets.
【Oncology-driven growth acceleration】 Management expects significant near-term catalysts to drive portfolio momentum, including the anticipated approval and launch of Ziihera in first-line gastroesophageal adenocarcinoma in the second half of 2026, which is positioned to become the preferred HER2-directed therapy based on unprecedented median overall survival data exceeding two years. The company anticipates continued strong adoption of Epidiolex and Modeyso, with double-digit growth expected in the rare oncology and epilepsy segments in 2026, supported by ongoing clinical trial readouts including interim overall survival data from the HERIZON-GEA trial mid-year and the ACTION trial for Modeyso expected by year-end or early 2027. In the sleep franchise, while XYWAV is expected to remain differentiated as the only FDA-approved low-sodium treatment for idiopathic hypersomnia, the company anticipates competitive pressures in the second half of 2026 from generic high-sodium oxybates and potential new wake-promoting agents, though XYWAV is expected to maintain its market position given its safety profile and established payer coverage. Management remains actively engaged in business development, expecting to announce deals over the course of 2026 focused on expanding the company's presence in rare disease, particularly in epilepsy and oncology, while maintaining disciplined capital allocation supported by strong operating cash flows and a robust balance sheet.
| Metric | Target | Period |
|---|---|---|
| Total Revenue | $4.25 billion–$4.50 billion | FY2026 |
| Rare Sleep Revenue | $1.8 billion–$1.9 billion | FY2026 |
| Non-GAAP Adjusted Gross Margin % | 90%–91% | FY2026 |
| Non-GAAP Adjusted Effective Tax Rate | 11.5%–13.5% | FY2026 |
| Fully Diluted Shares Outstanding | 65 million–66 million | FY2026 |
Total Revenue (FY2026): “we are reaffirming our full year 2026 revenue and expense guidance, including total revenue guidance of $4.25 billion-$4.5 billion”
Rare Sleep Revenue (FY2026): “We expect total rare sleep revenue of $1.8 billion-$1.9 billion, which represents a modest decrease from 2025”
Non-GAAP Adjusted Gross Margin % (FY2026): “Our non-GAAP adjusted gross margin % guidance is 90%-91%”
Non-GAAP Adjusted Effective Tax Rate (FY2026): “We expect our non-GAAP adjusted effective tax rate to be between 11.5% and 13.5%”
Fully Diluted Shares Outstanding (FY2026): “our guidance range for fully diluted shares outstanding is 65 million-66 million”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.4B | 4.3B | 4.1B | 3.8B | 3.7B | 3.1B |
| Net Income | 29M | -356M | 560M | 415M | -224M | -330M |
| EPS | $0.11 | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
| Free Cash Flow | 1.3B | 1.3B | 1.4B | 1.1B | 1.2B | 751M |
| ROIC | -0.6% | -3.8% | 12.8% | 8.6% | -0.8% | 1.8% |
| Gross Margin | - | 51.6% | 74.2% | 73.9% | 54.8% | 72.5% |
| Debt/Equity | 1.18 | 1.26 | 1.51 | 1.55 | 1.88 | 1.55 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -38M | -430M | 717M | 579M | -66M | 170M |
| Operating Margin | -0.9% | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% |
| ROE | 0.7% | -8.5% | 14.3% | 12.2% | -6.4% | -8.6% |
| Shares Outstanding | 66M | 61M | 65M | 68M | 63M | 60M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 1.2B | 1.3B | 1.5B | 1.6B | 1.9B | 2.2B | 2.4B | 3.1B | 3.7B | 3.8B | 4.1B | 4.3B | 4.4B |
| Gross Margin | N/A | N/A | N/A | 76.3% | 79.9% | 76.2% | 70.8% | 72.5% | 54.8% | 73.9% | 74.2% | 51.6% | N/A |
| R&D | 85M | 135M | 162M | 198M | 227M | 300M | 335M | 506M | 590M | 850M | 884M | 783M | 798M |
| SG&A | 406M | 449M | 503M | 544M | 684M | 737M | 854M | 1.5B | 1.4B | 1.3B | 1.4B | 1.8B | 1.6B |
| EBIT | 196M | 508M | 592M | 529M | 615M | 532M | 378M | 170M | -66M | 579M | 717M | -430M | -38M |
| Op. Margin | 16.7% | 38.4% | 39.8% | 32.7% | 32.5% | 24.6% | 16.0% | 5.5% | -1.8% | 15.1% | 17.6% | -10.1% | -0.9% |
| Net Income | 58M | 330M | 397M | 488M | 447M | 523M | 239M | -330M | -224M | 415M | 560M | -356M | 29M |
| Net Margin | 5.0% | 24.9% | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% | 0.7% |
| Non-Recurring | 3.6M | 33M | -47K | -473K | 49M | -21K | 136M | 0 | 96M | 0 | 5.7M | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 7.2% | 20.1% | 13.4% | 15.6% | 16.0% | 16.7% | 11.6% | 1.8% | -0.8% | 8.6% | 12.8% | -3.8% | -0.6% |
| ROE | 4.4% | 22.2% | 22.8% | 21.3% | 16.3% | 17.8% | 7.0% | -8.6% | -6.4% | 12.2% | 14.3% | -8.5% | 0.7% |
| ROA | 2.1% | 9.9% | 9.8% | 9.8% | 8.7% | 9.7% | 4.0% | -3.5% | -1.9% | 3.7% | 4.8% | -3.0% | 0.2% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 408M | 532M | 592M | 693M | 799M | 776M | 900M | 779M | 1.3B | 1.1B | 1.4B | 1.4B | 1.3B |
| Free Cash Flow | 371M | 496M | 583M | 664M | 779M | 736M | 885M | 751M | 1.2B | 1.1B | 1.4B | 1.3B | 1.3B |
| Owner Earnings | 323M | 430M | 482M | 573M | 681M | 651M | 760M | 563M | 1.0B | 835M | 1.1B | 1.0B | 984M |
| CapEx | 36M | 36M | 9.7M | 29M | 20M | 40M | 15M | 28M | 29M | 24M | 38M | 59M | 65M |
| Maint. CapEx | 15M | 9.9M | 12M | 13M | 15M | 15M | 19M | 27M | 30M | 30M | 33M | 42M | 52M |
| Growth CapEx | 21M | 26M | 0 | 16M | 5.2M | 25M | 0 | 941K | 0 | 0 | 5.3M | 17M | 13M |
| D&A | 15M | 9.9M | 12M | 13M | 15M | 15M | 19M | 27M | 30M | 30M | 33M | 42M | 52M |
| CapEx/OCF | 8.9% | 6.8% | 1.6% | 4.2% | 2.5% | 5.2% | 1.7% | 3.6% | 2.3% | 2.2% | 2.7% | 4.3% | 4.8% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 42M | 62M | 278M | 99M | 524M | 301M | 147M | 0 | 54K | 270M | 311M | 125M | 125M |
| Buyback Yield | 0.4% | 0.7% | 4.1% | 1.2% | 7.0% | 3.5% | 1.6% | N/A | 0.0% | 3.2% | 3.9% | 1.2% | 0.7% |
| Stock-Based Comp | 70M | 92M | 99M | 107M | 102M | 111M | 121M | 189M | 222M | 227M | 248M | 291M | 298M |
| Debt Repayment | 0 | 0 | 0 | 0 | 6.4M | 0 | 356M | 219M | 0 | 0 | 575M | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | 658M | 200M | 1.6B | 594M | 462M | 57M | -941M | 5.0B | 4.0B | 2.7B | 756M | 1.6B | 636M |
| Cash & Equiv. | 684M | 989M | 366M | 386M | 310M | 637M | 1.1B | 591M | 881M | 1.5B | 2.4B | 1.4B | 4.7B |
| Long-Term Debt | 1.3B | 1.2B | 2.0B | 1.5B | 1.6B | 1.6B | 1.8B | 6.0B | 5.7B | 5.1B | 6.1B | 4.3B | 4.3B |
| Debt/Equity | 0.98 | 0.74 | 1.08 | 0.58 | 0.58 | 0.57 | 0.61 | 1.55 | 1.88 | 1.55 | 1.51 | 1.26 | 1.18 |
| Interest Coverage | 5.9 | 19.2 | 21.5 | 14.0 | 10.8 | 8.5 | 4.3 | 1.9 | -2.0 | 17.6 | 1621.3 | -1162.8 | -1162.8 |
| Equity | 1.4B | 1.6B | 1.9B | 2.7B | 2.8B | 3.1B | 3.7B | 4.0B | 3.1B | 3.7B | 4.1B | 4.3B | 4.5B |
| Total Assets | 3.3B | 3.3B | 4.8B | 5.1B | 5.2B | 5.5B | 6.5B | 12.3B | 10.8B | 11.4B | 12.0B | 11.7B | 11.9B |
| Total Liabilities | 435M | 340M | 955M | 738M | 669M | 608M | 2.9B | 1.9B | 1.5B | 7.7B | 1.2B | 7.3B | -7.9M |
| Intangibles | 1.4B | 1.2B | 3.0B | 3.0B | 2.7B | 2.4B | 2.2B | 7.2B | 5.8B | 5.4B | 4.8B | 4.4B | 4.2B |
| Retained Earnings | 35M | 303M | 529M | 918M | 841M | 1.1B | 1.2B | 830M | 734M | 879M | 1.1B | 646M | 939M |
| Working Capital | 799M | 1.0B | 491M | 674M | 889M | 1.3B | 2.2B | 1.8B | 1.7B | 1.9B | 3.6B | 1.9B | 2.3B |
| Current Assets | 1.0B | 1.3B | 748M | 968M | 1.2B | 1.6B | 2.8B | 2.6B | 2.6B | 3.4B | 4.6B | 4.2B | 4.6B |
| Current Liabilities | 217M | 227M | 257M | 294M | 345M | 364M | 654M | 809M | 933M | 1.5B | 1.0B | 2.2B | 2.2B |
| Per Share Data | |||||||||||||
| EPS | 0.93 | 5.23 | 6.41 | 7.96 | 7.30 | 9.09 | 4.22 | -5.52 | -3.58 | 6.10 | 8.65 | -5.84 | 0.11 |
| Owner EPS | 5.14 | 6.83 | 7.78 | 9.35 | 11.12 | 11.30 | 13.44 | 9.42 | 16.29 | 12.28 | 17.22 | 16.78 | 14.89 |
| Book Value | 21.84 | 25.37 | 30.32 | 44.27 | 45.02 | 54.03 | 64.72 | 66.39 | 49.30 | 54.95 | 63.22 | 70.81 | 68.57 |
| Cash Flow/Share | 6.49 | 8.44 | 9.57 | 11.31 | 13.04 | 13.48 | 15.91 | 13.04 | 20.32 | 16.06 | 21.56 | 22.23 | 1.23 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 62.8M | 63.0M | 61.9M | 61.3M | 61.2M | 57.6M | 56.5M | 59.7M | 62.6M | 68.0M | 64.8M | 61.0M | 66.1M |
| Valuation | |||||||||||||
| P/E Ratio | 179.1 | 27.1 | 16.9 | 17.2 | 16.7 | 16.6 | 37.8 | N/A | N/A | 20.2 | 14.4 | N/A | N/A |
| P/FCF | 28.2 | 18.0 | 11.5 | 12.6 | 9.6 | 11.8 | 10.2 | 10.4 | 7.9 | 7.9 | 5.9 | 8.0 | 13.2 |
| EV/EBIT | 56.8 | 18.0 | 14.0 | 17.0 | 12.9 | 16.1 | 21.0 | 74.3 | N/A | 19.0 | 13.1 | N/A | N/A |
| Price/Book | 7.6 | 5.6 | 3.6 | 3.1 | 2.7 | 2.8 | 2.5 | 2.0 | 3.2 | 2.2 | 2.0 | 2.4 | 3.7 |
| Price/Sales | 8.1 | 7.9 | 5.4 | 5.4 | 5.1 | 3.6 | 3.1 | 3.0 | 2.5 | 2.4 | 1.8 | 1.8 | 3.8 |
| FCF Yield | 3.6% | 5.6% | 8.7% | 7.9% | 10.4% | 8.5% | 9.8% | 9.6% | 12.7% | 12.7% | 16.8% | 12.5% | 7.6% |
| Market Cap | 10.5B | 8.9B | 6.7B | 8.4B | 7.5B | 8.7B | 9.0B | 7.8B | 9.8B | 8.4B | 8.1B | 10.4B | 16.8B |
| Avg. Price | 151.96 | 165.63 | 129.97 | 142.95 | 157.69 | 133.57 | 128.01 | 155.31 | 149.04 | 135.40 | 114.87 | 127.65 | 253.87 |
| Year-End Price | 166.55 | 141.65 | 108.36 | 136.57 | 121.70 | 150.93 | 159.64 | 130.47 | 156.94 | 123.36 | 124.60 | 170.48 | 253.87 |
Jazz Pharmaceuticals plc passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 12.0x vs a median of 9.9x. The company's 5-year average ROIC is 3.7% with a gross margin of 65.4%. Total shareholder yield (buybacks) is 0.7%. At current prices, the estimated annualized return to fair value is +8.1%.
Jazz Pharmaceuticals plc (JAZZ) has a debt-to-equity ratio of 1.26. This indicates moderate leverage.
Jazz Pharmaceuticals plc (JAZZ) reported earnings per share (EPS) of $-5.84 in its most recent fiscal year.
Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of -8.5%. A negative ROE may indicate losses or negative equity.
Jazz Pharmaceuticals plc (JAZZ) has a 5-year average gross margin of 65.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for Jazz Pharmaceuticals plc (JAZZ), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Jazz Pharmaceuticals plc (JAZZ) has a book value per share of $70.81, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects significant near-term catalysts to drive portfolio momentum, including the anticipated approval and launch of Ziihera in first-line gastroesophageal adenocarcinoma in the second half of 2026, which is positioned to become the preferred HER2-directed therapy based on unprecedented median overall survival data exceeding two years. The company anticipates continued strong adoption of Epidiolex and Modeyso, with double-digit growth expected in the rare oncology and epilepsy segments in 2026, supported by ongoing clinical trial readouts including interim overall survival data from the HERIZON-GEA trial mid-year and the ACTION trial for Modeyso expected by year-end or early 2027. In the sleep franchise, while XYWAV is expected to remain differentiated as the only FDA-approved low-sodium treatment for idiopathic hypersomnia, the company anticipates competitive pressures in the second half of 2026 from generic high-sodium oxybates and potential new wake-promoting agents, though XYWAV is expected to maintain its market position given its safety profile and established payer coverage. Management remains actively engaged in business development, expecting to announce deals over the course of 2026 focused on expanding the company's presence in rare disease, particularly in epilepsy and oncology, while maintaining disciplined capital allocation supported by strong operating cash flows and a robust balance sheet.
Based on recent SEC filings and earnings calls, Jazz Pharmaceuticals plc (JAZZ) has provided the following forward guidance: Total Revenue: $4.25 billion–$4.50 billion (FY2026); Rare Sleep Revenue: $1.8 billion–$1.9 billion (FY2026); Non-GAAP Adjusted Gross Margin %: 90%–91% (FY2026); Non-GAAP Adjusted Effective Tax Rate: 11.5%–13.5% (FY2026); Fully Diluted Shares Outstanding: 65 million–66 million (FY2026).